Skip to main content

Table 2 Adverse events

From: A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma

Event Grade 3/4 (n) % Total (n) %
Any event 13 76% 17 100%
Anemia 4 24% 14 82%
Anorexia 0 0% 6 35%
Arthralgia 1 6% 7 41%
Chills 0 0% 10 59%
Constipation 0 0% 4 24%
Cough 0 0% 3 18%
Decreased urine output 1 6% 1 6%
Diarrhea 1 6% 7 41%
Dry skin 0 0% 15 88%
Dyspnea 0 0% 3 18%
Edema 0 0% 14 82%
Fatigue 0 0% 14 82%
Fever 0 0% 5 29%
Headache 0 0% 7 41%
Hyperglycemia 1 6% 6 35%
Hyperkalemia 1 6% 4 24%
Hypermagnesiumia 1 6% 1 6%
Hypertension 1 6% 2 12%
Hyperuricemia 2 12% 4 24%
Hypoalbuminemia 8 47% 14 82%
Hypoglycemia 0 0% 5 29%
Hyponatremia 1 6% 2 12%
Hypophosphatemia 0 0% 3 18%
Hypotension 0 0% 7 41%
Increased alanine aminotransferase 0 0% 3 18%
Increased alkaline phosphatase 0 0% 3 18%
Increased aspartate aminotransferase 0 0% 5 29%
Increased bilirubin 2 12% 6 35%
Increased Creatinine 2 12% 6 35%
Injection site reaction 0 0% 5 29%
Lymphopenia 3 18% 4 24%
Myalgia 0 0% 10 59%
Nausea 0 0% 11 65%
Pain 1 6% 12 71%
Peripheral sensory neuropathy 0 0% 7 41%
Pruritus 1 6% 12 71%
Rash 1 6% 8 47%
Thrombocytopenia 1 6% 2 12%
Tinnitus 0 0% 3 18%
Ventricular tachycardia 1 6% 2 12%
Vomiting 0 0% 7 41%
Weight loss 0 0% 3 18%
  1. Events occurring in > 15% of patients and all Grade 3/4 adverse events